MYC and neoplasm: MYC transgenic mice develop prostate PIN/tumor lesions with increasing age, and treatment of the mice with ENZ or abiraterone (ABI) at 4 months of age inhibited prostate growth but CRPC emerged at 7 months of age (Figure 5E).